SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Provectus Biopharmaceuticals, Inc. (NYSE: PVCT) violated state or federal laws.
On May 20, 2014, TheStreet.com published an article stating that Provectus had originally described its PV-10 drug as a “breakthrough cancer drug” on its website. Subsequently, the drug description on the website was changed to “an investigational drug for cancer.”
On May 21, 2014, an article published by Seeking Alpha cited that “PVCT is connected to questionable paid stock promoters whose other recommendations have recently been halted by the SEC”. The article continued that “PV-10 has no Phase 3 trial in sight while patents begin expiring in 2016 and appears to have failed their FDA Breakthrough Designation Request.”
Since the release of the above articles, PVCT shares have fallen over 24% in trading. On May 23, 2014, trading in Provectus’ stock was halted at $2.02 per share.
If you are a Provectus shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (email@example.com) at 619-814-4471. If you email, please include your phone number.
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California and New York. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.